Cerus INTERCEPT Red Blood Cells Meet Primary Efficacy Endpoint in Phase 3 Trial

• Cerus announced Phase 3 RedeS results showing INTERCEPT-treated red blood cells met the primary efficacy endpoint, demonstrating non-inferiority to conventional cells.
• Transfusion-related adverse events showed no statistically significant difference between treatment groups.
• Temporary, low-level INTERCEPT-specific antibodies appeared in some treated patients without evidence of red blood cell destruction or clinical impact.
• The INTERCEPT Blood System for Red Blood Cells remains investigational in the U.S., without FDA approval.
• Full results are expected to be submitted to a peer-reviewed journal and presented at upcoming scientific meetings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611021600BIZWIRE_USPR_____20261102_BW143597) on November 02, 2026, and is solely responsible for the information contained therein.